This annual session is an opportunity for all interested stakeholders to get the latest information about priority initiatives and process changes from CADTH’s pharmaceutical reviews portfolio, including the CADTH Common Drug Review (CDR), the CADTH pan-Canadian Oncology Drug Review (pCODR), and Therapeutic Reviews. Updates on other relevant CADTH initiatives will also be provided. The session also includes an Open Forum where attendees can direct questions to CADTH President and CEO Dr. Brian O’Rourke, and other senior staff at CADTH.
The session will be presented in English and can be attended in person or by webinar. There is no charge to attend but advance registration is required. closes on Thursday, October 25, 2018.
Questions may be sent by email to Events@cadth.ca.